Coya Therapeutics annual return on equity
2023
2024
2025
Coya Therapeutics Return on Equity (ROE) Growth & History (COYA)
Coya Therapeutics's return on equity was −51.39% for fiscal 2025.
View full Coya Therapeutics company overviewCoya Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −51.39% | −11.82 pp |
| 2024 | 2024-12-31 | −39.57% | +19.07 pp |
| 2023 | 2023-12-31 | −58.64% | — |
Coya Therapeutics quarterly return on equity
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −14.39% | +5.37 pp |
| Q1 2026 | 2026-03-31 | −15.67% | +4.37 pp |
| Q4 2025 | 2025-12-31 | −16.24% | −8.09 pp |
| Q3 2025 | 2025-09-30 | −7.61% | +4.35 pp |
| Q2 2025 | 2025-06-30 | −19.76% | −11.21 pp |
| Q1 2025 | 2025-03-31 | −20.03% | −5.18 pp |
| Q4 2024 | 2024-12-31 | −8.15% | −13.68 pp |
| Q3 2024 | 2024-09-30 | −11.96% | +17.37 pp |
| Q2 2024 | 2024-06-30 | −8.55% | +12.51 pp |
| Q1 2024 | 2024-03-31 | −14.85% | +55.69 pp |
| Q4 2023 | 2023-12-31 | 5.54% | — |
| Q3 2023 | 2023-09-30 | −29.33% | — |
| Q2 2023 | 2023-06-30 | −21.06% | — |
| Q1 2023 | 2023-03-31 | −70.54% | — |
Coya Therapeutics return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Coya Therapeutics's return on equity increased from −58.64% to −51.39%, a change of +7.25 percentage points. The latest reported quarter, Q2 2026, shows −14.39%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Coya Therapeutics source filings ↗